Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up



Status:Completed
Conditions:Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:18 - Any
Updated:12/27/2018
Start Date:November 2015
End Date:November 2017

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The objective of the trial is to compare the short term efficacy of LEO 43204 gel with
vehicle gel in AK on face or chest when applied topically once daily for 3 consecutive days
as field treatment.


Inclusion Criteria:

- Subjects with 5 to 20 clinically typical, visible and discrete AKs within a treatment
area of sun-damaged skin on either the full face or a contiguous area of approximately
250 cm2 (40 in2) on the chest

- Subjects with minimum 3 clinically typical, visible and discrete AKs within a tracking
area of 50 cm2 (8 in2). The tracking area must be within the treatment area

Exclusion Criteria:

- Location of the treatment area (full face or chest) within 5 cm of an incompletely
healed wound or within 5 cm of a suspected BCC or SCC

- Treatment with ingenol mebutate gel in the treatment area within the last 12 months

- Lesions in the treatment area that have: atypical clinical appearance (e.g.
hyperthrophic, hyperkeratotic or cutaneous horns) and /or, recalcitrant disease (e.g.
did not respond to cryotherapy on two previous occasions)

- History or evidence of skin conditions other than the trial indication that would
interfere with the evaluation of the trial medication (e.g., eczema, unstable
psoriasis, xeroderma pigmentosum)
We found this trial at
1
site
Altman Dermatology Associates
Arlington Heights, Illinois 60005
Principal Investigator: Michael Bukhalo, MD
Phone: 847-392-5440
?
mi
from
Arlington Heights, IL
Click here to add this to my saved trials